$KDNY

Chinook Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Commercial Services
  • Miscellaneous Commercial Services
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$15.01 ▲8.375%

Last Close

VOLUME

1,180,370

DAY RANGE

13.71 - 15.47

52 WEEK

10.48 - 19.85

Join Discuss about KDNY with like-minded investors

profile
@dros #droscrew
recently

+Initiations 1/6: $ARDX $AYX $DNMR $KDNY $LAZR $NBTX $NLTX $OPEN $PTGX $SCYX $SEIC $SRRK $VINC $VLDR $VSTO $WELL . -Initiations 1/6: $SCCO

83 Replies 15 👍 8 🔥

profile
@dros #droscrew
recently

+Initiations 10/7: $CNTG $DT $HEI $IDYA $IIVI $KDNY $NEWR $NFIN $NOVA $PEN $SPWR $SWI -Initiations 10/7: $GSKY

148 Replies 13 👍 15 🔥

profile
@Pyrognosis #droscrew
recently

New option listings for October 6th include Chinook Therapeutics Inc (KDNY) and Palantir Technologies Inc (PLTR) (Class A Stock) (PLTR). Option delistings effective October 6th include Aduro Biotech Inc ( ADRO) , TD Ameritrade Holding Corporation ( AMTD) , and Noble Energy Inc (NBL).

133 Replies 9 👍 10 🔥

Key Metrics

Market Cap

828.21 M

Beta

1.27

Avg. Volume

527.60 K

Shares Outstanding

55.18 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-11

Next Dividend Date

Company Information

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.

CEO: Stephen Isaacs

Website:

HQ: 740 Heinz Ave Berkeley, 94710-2748 California

Related News